8-K: Veradigm to be Delisted from Nasdaq Due to Non-Compliance

Veradigm Inc. has received notice of delisting from Nasdaq due to non-compliance with listing rules, with trading suspension effective February 29, 2024.

Summary

• Veradigm Inc. received a delisting notice from Nasdaq because it failed to file its 2022 annual report and several quarterly reports.
• The company also failed to hold an annual meeting within the required timeframe.
• Trading of Veradigm's common stock on Nasdaq will be suspended starting February 29, 2024.
• The company's stock is expected to trade on an over-the-counter market under the existing ticker symbol MDRX.
• The delisting triggers a make-whole fundamental change for the company's convertible notes.
• Veradigm is working to file the overdue reports and regain compliance with Nasdaq listing rules, but there is no guarantee of success or a timeline for relisting.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the delisting notice, indicating significant issues with the company's compliance and financial reporting. The lack of a clear timeline for resolution and the potential risks associated with over-the-counter trading further contribute to the negative sentiment.

Positives

• Veradigm is working diligently to file the overdue reports and regain compliance with Nasdaq listing rules.
• The company expects its shares to be quoted on an over-the-counter market, allowing continued trading.

Negatives

• Veradigm has received a delisting notice from Nasdaq.
• Trading of the company's stock on Nasdaq will be suspended.
• The company has failed to file its 2022 annual report and several quarterly reports.
• The company has failed to hold an annual meeting within the required timeframe.
• The delisting triggers a make-whole fundamental change for the company's convertible notes.

Risks

• There is no assurance that Veradigm will be able to file the overdue reports or regain compliance with Nasdaq listing rules.
• The company's stock may experience increased volatility and decreased liquidity trading on the over-the-counter market.
• The ongoing independent investigation by the Audit Committee could further delay financial reporting.
• The company faces risks related to a securities class action lawsuit and potential future litigation.
• Holders of convertible notes have the right to put the notes to the company or convert them into stock due to the delisting.

Future Outlook

Veradigm is working to regain compliance with Nasdaq listing rules and restore its listing, but there is no guarantee of success or a timeline for relisting. The company expects its shares to be quoted on an over-the-counter market while suspended from Nasdaq.

Management Comments

• The company is working diligently to file the Form 10-K and the Form 10-Qs, and ultimately to regain compliance with all of the Nasdaq Listing Rules and restore its listing as soon as practicable.
• The company does not intend to request that the Nasdaq Listing and Hearing Review Council review the Decision.

Industry Context

This delisting highlights the importance of timely financial reporting and adherence to listing requirements for publicly traded companies. It also underscores the potential consequences of internal control issues and accounting irregularities.

Comparison to Industry Standards

• Many companies in the healthcare technology sector are listed on major exchanges like Nasdaq and the NYSE, and are expected to maintain compliance with all listing rules.
• Companies like Allscripts Healthcare Solutions and Cerner Corporation, which are competitors of Veradigm, have maintained their listings and have not faced similar delisting issues.
• The failure to file financial reports and hold an annual meeting is a significant deviation from industry standards for publicly traded companies.

Legal Proceedings

• The company is facing a putative securities class action lawsuit related to the Audit Committee Investigation.

Stakeholder Impact

• Shareholders will be negatively impacted by the delisting and the potential for decreased liquidity and increased volatility.
• Holders of convertible notes have the right to put the notes to the company or convert them into stock due to the delisting.
• Employees may experience uncertainty due to the company's financial and compliance issues.

Next Steps

• Veradigm will work to file the overdue Form 10-K and Form 10-Qs.
• The company will seek to regain compliance with Nasdaq listing rules.
• The company's stock will be quoted on an over-the-counter market.

Key Dates

Keywords

delisting, Nasdaq, non-compliance, financial reporting, Form 10-K, Form 10-Q, over-the-counter, convertible notes, MDRX, Audit Committee Investigation